﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Epidemiology</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Epidemiology"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.01.26357045v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.01.26356511v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.01.26357005v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.07.02.26357114v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.30.26356042v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.30.26356962v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.30.26356931v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.30.26356925v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.30.26356947v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.30.26356940v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.29.26356808v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.24.26356335v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.29.26356899v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.30.26356834v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.27.26356735v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.29.26354430v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.24.26356254v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.24.26356453v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.29.26356818v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.27.26356627v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.29.26356883v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.28.26356782v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.24.26356456v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.26.26356705v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.26.26356648v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.26.26356655v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.26.26356687v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.23.26355971v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.25.26356562v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.06.24.26356484v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.01.26357045v1?rss=1">
<title>
<![CDATA[
A simplified antigen-based serological algorithm accurately classifies MPXV exposure and vaccination status 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.01.26357045v1?rss=1
</link>
<description><![CDATA[
Reliable serological tools are needed to measure mpox virus (MPXV) exposure, evaluate vaccine-induced immunity, and support population-level surveillance. Using a previously established six-antigen serological reference framework, in which seropositivity was defined as reactivity to [&ge;]4 of 6 MPXV antigens, we evaluated the diagnostic performance of individual antigens and all 15 pairwise combinations. B6R demonstrated the highest overall individual discriminatory performance, whereas A35R showed maximal sensitivity and M1R the highest specificity. The A35R+B6R combination most closely approximated the full multiplex assay (AUC 0.93), supporting simplified, scalable MPXV serological assays for surveillance and vaccine evaluation.
]]></description>
<dc:creator><![CDATA[ Abdullahi, A., Adebisis, G., Wisso, H., Osawe, S., Kampmann, B., Abimiku, A., Gupta, R. K. ]]></dc:creator>
<dc:date>2026-07-04</dc:date>
<dc:identifier>doi:10.64898/2026.07.01.26357045</dc:identifier>
<dc:title><![CDATA[A simplified antigen-based serological algorithm accurately classifies MPXV exposure and vaccination status]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.01.26356511v1?rss=1">
<title>
<![CDATA[
Designing infection prevalence and seroprevalence surveys for learning infection dynamics 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.01.26356511v1?rss=1
</link>
<description><![CDATA[
Knowledge of the true number of infections over time is valuable for accurately predicting the future course of an epidemic and planning effective interventions, but the number of cases reported offers only a noisy underestimate of the true number of infections. Disease surveillance strategies based on assessing subsets of the population for current infection (infection prevalence surveys) or antibody presence (seroprevalence surveys) yield crucial information about the number truly infected, but are expensive. To explore impact of survey design considerations--both sample size and sampling frequency--on inference of the number of incident infections over time, we coupled agent-based simulations of respiratory virus epidemics with simulations of infection prevalence and seroprevalence surveys. While returns diminish with increased sample size, we find inference generally improved by increasing survey frequency relative to participants-per-round for any given sample size. After survey rounds reach a sufficient frequency, comparable inference performance may be achieved with either more frequent rounds or more participants per round. Rolling designs with tests conducted each day tend to outperform designs in which testing is divided into discrete rounds. We also show that misspecified assumptions about seroreversion may substantially decrease the quality of inference results.
]]></description>
<dc:creator><![CDATA[ Creswell, R., Golding, N., Ryan, G. E., Eales, O., Price, D. J., McCaw, J. M., Shearer, F. M. ]]></dc:creator>
<dc:date>2026-07-04</dc:date>
<dc:identifier>doi:10.64898/2026.07.01.26356511</dc:identifier>
<dc:title><![CDATA[Designing infection prevalence and seroprevalence surveys for learning infection dynamics]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.01.26357005v1?rss=1">
<title>
<![CDATA[
Prevalence and determinants of respiratory symptoms and functional disorders among children exposed to particulate matter through domestic and maternal occupational solid fuel use in Abidjan, Cote dIvoire - a cross-sectional study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.01.26357005v1?rss=1
</link>
<description><![CDATA[
ABTRACT Background Children from low- and middle-income countries are particularly vulnerable to air pollution, a major environmental health risk, due to the immaturity of their lungs and their proximity to sources of household pollution. This study aimed to investigated the effect of exposure to biomass combustion through domestic and maternal occupational activities on respiratory health of children living in disadvantaged urban areas of Abidjan, Cote dIvoire. Methods Between February and December 2023, we conducted a cross-sectional observational study among children <16 years from households of women using biomass fuel for cooking (Group (G) 1), engaged in occupational fish smoking activities (G2), or primarily using gas for domestic cooking (G3). We assessed reported respiratory symptoms through standardized questionnaires and the presence of lung function impairments (LFI) though pulmonary function tests (spirometry and Rint). We assessed the association between study groups and key covariates with respiratory symptoms and LFI using mixed-effects regression models. Results Of 210 children enrolled - 119 (56.8%) female, median age 9 (6-12) years, 82 (39.0%) in G1, 47 (22.4%) in G2, and 81 (38.6%) in G3 - 15 (7.1%) reported wheezing in the last 12 months, 82 (39.0%) reported dry cough at night, 9 (4.9%) presented with dyspnea and 5 (2.7%) had chest pain on clinical examination, for an overall proportion of children with reported respiratory symptoms of 43.8% (92/210). Of 176 children who underwent pulmonary function testing, 59 (33.5%) had LFI detected, including 34 (45.9%) in G1, 8 (22.2%) in G2, and 17 (25.8%) in G3 (p = 0.011). Study group was associated with respiratory symptoms (G1 vs G3; aOR 3.82, 95% CI 1.68-8.68; p < 0.001), as well as with LFI (p = 0.042). Girls were at greater risk of LFI than boys (aOR 2.69, 95% CI 1.24-5.80; p = 0.012). Children whose mothers used charcoal or wood as cooking fuel had higher odds of respiratory symptoms (OR 2.61, 95% CI 1.22-5.58; p = 0.013) but no association was found with LFI (p = 0.459) compared with unexposed children. Conclusion Respiratory symptoms and lung function impairments were highly prevalent among children living disadvantaged, especially when mothers cook with wood or charcoal. Targeted maternal awareness and broader interventions to reduce household air pollution in disadvantaged urban areas are urgently needed to protect long-term respiratory health.
]]></description>
<dc:creator><![CDATA[ Pajot, A., Dje, S. A., Tanoh, F. D. A., Liousse, C., Thivillon, T., Doumbia, M., Gnamien, S., Marie, Y., Fayon, M., Yoboue, V., Marcy, O. ]]></dc:creator>
<dc:date>2026-07-04</dc:date>
<dc:identifier>doi:10.64898/2026.07.01.26357005</dc:identifier>
<dc:title><![CDATA[Prevalence and determinants of respiratory symptoms and functional disorders among children exposed to particulate matter through domestic and maternal occupational solid fuel use in Abidjan, Cote dIvoire - a cross-sectional study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.07.02.26357114v1?rss=1">
<title>
<![CDATA[
Identifying implementation units that would benefit from alternative treatment strategies to accelerate the elimination of onchocerciasis transmission in Africa 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.07.02.26357114v1?rss=1
</link>
<description><![CDATA[
Background: The World Health Organization proposes that elimination of onchocerciasis transmission (EOT) be verified in 12 endemic countries by 2030. In sub-Saharan Africa (SSA), where most cases occur, Niger is the only country that has been verified to date. Despite decades of ivermectin mass drug administration (MDA), infection persists in West and Central Africa. Alternative treatment strategies (ATS) are necessary to accelerate progress towards EOT by 2030 and beyond. Methods: We used the EPIONCHO-IBM transmission model to project the number of years, from 2026, to reduce microfilarial (mf) prevalence below 1% across 1,634 implementation units (IUs) in 19 SSA countries. We fitted the model to geostatistically-derived mf prevalence in 1975, 2000 and 2018, and projected mf prevalence through to 2025. We classified IUs according to their baseline endemicity, intervention history programmatic performance, and current (2025) MDA frequency (annual or biannual). For those IUs that would not reach < 1% mf prevalence by 2030 if current strategies were continued, we simulated ATS (increasing treatment frequency, improving coverage, and adopting moxidectin MDA) from 2026 to 2040. Results: Of the 1,486 IUs currently under annual ivermectin MDA, 45% would require ATS. In those low-moderate endemicity IUs, biannual ivermectin would have a comparable impact to that of switching to annual moxidectin; in those with high endemicity, adopting biannual moxidectin would be more impactful. Of the 148 IUs currently receiving biannual ivermectin, 24% would benefit from ATS, switching to biannual moxidectin being the best option. Conclusion: This work brings into sharper focus which IU profiles are most likely to require ATS across SSA. In highly-endemic IUs with long intervention histories, biannual moxidectin MDA may be required under our modelling assumptions, with substantial uncertainty surrounding the permanent sterilising effect, of the two drugs under comparison, upon adult female worms. National programmes aiming to reach EOT will have options that need to be balanced against financial considerations. Implementation studies will also be important for translating these modelling projections into national policy decisions, particularly where different intervention strategies generate similar epidemiological benefits. Economic and epidemiological evaluations of repeated moxidectin MDA are needed to inform these decisions.
]]></description>
<dc:creator><![CDATA[ Ramani, A., Dixon, M. A., Walker, M., Browning, R., Konzen, E., Spencer, S. E. F., Fronterre, C., Basanez, M.-G. ]]></dc:creator>
<dc:date>2026-07-04</dc:date>
<dc:identifier>doi:10.64898/2026.07.02.26357114</dc:identifier>
<dc:title><![CDATA[Identifying implementation units that would benefit from alternative treatment strategies to accelerate the elimination of onchocerciasis transmission in Africa]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.30.26356042v1?rss=1">
<title>
<![CDATA[
Cancer trends in England in younger adults from 2001-2023: comparing incidence, mortality and stage at diagnosis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.30.26356042v1?rss=1
</link>
<description><![CDATA[
ObjectivesTo compare trends in incidence and mortality rates for cancers with rising incidence in younger adults in England, and to assess whether increasing incidence is observed for early-stage, late-stage or both types of disease.

Methods and analysisWe used cancer incidence and mortality data from English National Disease Registration Service (2001-2023). Analyses focused on 12 cancers with increasing incidence (on average) in younger adults (20-49 years) and more than 500 cases diagnosed in 2023. Trends were quantified by estimating the average annual percentage changes (AAPCs) and 95% confidence intervals (CI) using Joinpoint regression and by calculating the excess number of cancer cases in 2023 compared to 2001. Age-standardised rates (ASRs) of early (stage 1-2) and late-stage (stage 3-4) disease were compared between 2013 (the earliest year available) to 2023.

ResultsThere were 31,385 cancers diagnosed in younger adults in 2023 compared to 244,384 in older adults. The most common cancers diagnosed in younger adults were female breast (n=8,504), colorectal (n=2,977) and melanoma (n=2,767). Of the 12 cancers that were increasing in younger adults between 2001 and 2023, only two also had increasing mortality rates: endometrial (AAPC[95%CI]= incidence 2.9%[2.4-3.4%] and mortality 4.0%[2.1-6.0%]) and colorectal cancer (AAPC[95%CI]= incidence 3.2%[2.8-3.6%] and mortality 1.9%[1.1-2.7%]). For thyroid cancer mortality rates were stable and for the other cancers (female breast, testicular, ovarian, kidney, brain, prostate, Hodgkin lymphoma and leukaemia) although incidence rates were increasing, mortality rates were decreasing, on average. Of the ten cancers with available stage data six showed increases in incidence rates for both early and late-stage disease between 2013 and 2023. Four cancers showed increases only in late-stage disease (female breast, ovarian, melanoma and Hodgkin lymphoma), while thyroid cancer showed an increase only in early-stage disease.

ConclusionsThese population-wide analyses of national data from England, combining cancer incidence, mortality and stage-stratified incidence trends, highlight several public health and research priorities. These include identifying the causes of increasing colorectal cancer incidence in younger adults, given the marked increases in mortality and late-stage disease, and of increasing breast cancer incidence, which affects the largest number of younger adults and is increasing only for late-stage disease.

KEY MESSAGESO_ST_ABSWhat is already known on this topicC_ST_ABSIncidence rates for several cancers are rising among younger adults in England. Data from the USA has shown increases in late-stage disease for several cancers increasing in younger adults, but parallel increases in mortality have been observed only for colorectal and endometrial cancer.

What this study addsIn younger adults, incidence rates of late-stage disease increased from 2013-2023 for all cancers with available stage data except thyroid cancer. However, only endometrial and colorectal cancer showed parallel increases in mortality rates from 2001-2023. Despite these increases, the absolute numbers of diagnoses and deaths remained relatively small compared to those in older adults (age 50+).

How this study might affect research, practice or policyThis study identifies current priorities for research and cancer prevention, interception and early detection in younger adults, underscoring the need for in-depth investigation of cancers with concurrent increases in incidence, mortality, and both for both early- and late-stage disease.
]]></description>
<dc:creator><![CDATA[ berrington de gonzalez, a., O'Brien, E., Richards, Z., Frost, R., Shiels, M., Macklin-Doherty, A., Garcia-Closas, M. ]]></dc:creator>
<dc:date>2026-07-02</dc:date>
<dc:identifier>doi:10.64898/2026.06.30.26356042</dc:identifier>
<dc:title><![CDATA[Cancer trends in England in younger adults from 2001-2023: comparing incidence, mortality and stage at diagnosis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.30.26356962v1?rss=1">
<title>
<![CDATA[
Interaction-based metabolomics identifies serum modifiers of the clinical expression of Alzheimer's disease pathology 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.30.26356962v1?rss=1
</link>
<description><![CDATA[
IntroductionDeveloping interventions for Alzheimers disease (AD) requires an improved understanding of mechanisms linking biological pathology to the penetrance of, and resilience to, cognitive impairment. This research identifies blood metabolites that are associated with cognitive impairment adjusting for the presence of AD pathology.

MethodsMass spectrometry peaks (n=2,282) were screened using mutually conditioned models (N=154; cross-adjusting CSF-biomarker defined AD status and cognitive status). Peaks were then tested for multiplicative interactions (CSF biomarker x peak) against both endpoints using complete APOE-{varepsilon}4 and albumin CSF/serum quotient data (N=140).

ResultsThe screen revealed two directional profiles: Profile I (negative with status; positive with cognition) and Profile II (positive with status; negative with cognition). Secondary interaction modeling identified four peaks with interactions significantly associated with AD, and two with cognitive impairment, including one annotated as cerebroside B.

DiscussionThese interaction patterns indicate peripheral features acting as context-dependent modulators of AD pathology and cognitive symptom penetrance rather than global risk indicators, improving clinical stratification.
]]></description>
<dc:creator><![CDATA[ Helkkula, P., Rabl, M., Clark, C., Stojkovic, S., Popp, J. ]]></dc:creator>
<dc:date>2026-07-02</dc:date>
<dc:identifier>doi:10.64898/2026.06.30.26356962</dc:identifier>
<dc:title><![CDATA[Interaction-based metabolomics identifies serum modifiers of the clinical expression of Alzheimer's disease pathology]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.30.26356931v1?rss=1">
<title>
<![CDATA[
Prognostic Association of Handgrip-Defined Probable or Possible Sarcopenia Status and Polygenic Risk with 10-Year Fracture Incidence among Black, Hispanic, and White Women: A Women's Health Initiative Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.30.26356931v1?rss=1
</link>
<description><![CDATA[
PurposeThe Fracture Risk Assessment Tool (FRAX) excludes objective skeletal muscle health and genetic variables. We evaluated the prognostic associations of handgrip-defined probable/possible sarcopenia and genome-wide polygenic scores (GPS) with 10-year fracture risk, and their incremental predictive value beyond FRAX across racial/ethnic groups and GPS strata.

MethodsWe analyzed 2,051 postmenopausal women from the Womens Health Initiative. Race-specific analyses focused on Black, Hispanic, and White participants (n=2,009), excluding American Indian/Alaska Native and Asian/Pacific Islander individuals due to sparse fracture events. Sarcopenia status was operationalized by low handgrip strength alone via EWGSOP2 (<16.0 kg) and AWGS 2025 (<18.0-20.0 kg) criteria. Fine-Gray models estimated subdistribution hazard ratios (sHR), treating death as a competing risk. Predictive performance at 10 years was assessed using time-dependent AUC, Brier scores, and decision curve analysis (DCA).

ResultsHandgrip-defined probable or possible sarcopenia prevalence was 4.4% (EWGSOP2) and 6.4% (AWGS 2025). Black women demonstrated lower risk for major osteoporotic fractures (MOF) (adjusted sHR=0.19, 95% CI: 0.08-0.48) and hip fractures (adjusted sHR=0.07, 95% CI: 0.01-0.52) compared to White women. Neither sarcopenia status nor high GPS showed statistically significant independent associations with fractures after FRAX adjustment. Adding sarcopenia status to baseline FRAX (AUC: 0.71 for MOF; 0.69 for hip) yielded near-identical AUCs, Brier scores, and within-sample net benefit.

ConclusionHandgrip-defined probable/possible sarcopenia and current GPS do not provide independent or incremental predictive value beyond the clinical FRAX framework within this genomic sub-sample of older women.

Mini AbstractThe Fracture Risk Assessment Tool (FRAX) currently excludes skeletal muscle and genomic metrics. In 2,051 postmenopausal women, incorporating handgrip-defined sarcopenia and polygenic scores provided no incremental predictive benefit beyond standard FRAX. Within this study population, separate integration of these markers may not enhance routine fracture risk stratification.
]]></description>
<dc:creator><![CDATA[ Jung, J., Wu, Q. ]]></dc:creator>
<dc:date>2026-07-02</dc:date>
<dc:identifier>doi:10.64898/2026.06.30.26356931</dc:identifier>
<dc:title><![CDATA[Prognostic Association of Handgrip-Defined Probable or Possible Sarcopenia Status and Polygenic Risk with 10-Year Fracture Incidence among Black, Hispanic, and White Women: A Women's Health Initiative Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.30.26356925v1?rss=1">
<title>
<![CDATA[
PrEP-associated screening reduces N. gonorrhoeae transmission but increases case notifications among MSM: a modeling study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.30.26356925v1?rss=1
</link>
<description><![CDATA[
The rapid scale-up of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men has coincided with rising rates of bacterial sexually transmitted infections (STIs), particularly Neisseria gonorrhoeae. This temporal association has raised concerns that PrEP may be driving a new STI epidemic. However, the epidemiological impact of PrEP reflects a trade-off between potential behavioral risk compensation, which increases transmission risk, and intensified clinical surveillance, which shortens infection duration. Determining whether PrEP amplifies or mitigates STI transmission therefore requires understanding how these competing effects balance at the population level. To address this question, we develop a transmission model stratified by sexual activity and PrEP use, derive simple analytical conditions governing changes in prevalence, incidence, and notification rates, and evaluate these dynamics using empirically informed parameter estimates. Our analysis demonstrates that current quarterly screening guidelines are generally sufficient to reduce both the true endemic prevalence and incidence of N. gonorrhoeae, successfully overcompensating for plausible reductions in condom use. We also confirm and expand on previous findings that clinical notification rates may surge even as the true disease burden declines, driven by the detection of previously undiagnosed asymptomatic infections. These findings suggest a shift in focus from the potential impact of PrEP on STI transmission to the consequences of increased STI diagnoses and treatment, particularly whether greater antibiotic consumption may accelerate the spread of antimicrobial resistance in N. gonorrhoeae.
]]></description>
<dc:creator><![CDATA[ Marrec, L., Lehtinen, S. ]]></dc:creator>
<dc:date>2026-07-02</dc:date>
<dc:identifier>doi:10.64898/2026.06.30.26356925</dc:identifier>
<dc:title><![CDATA[PrEP-associated screening reduces N. gonorrhoeae transmission but increases case notifications among MSM: a modeling study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.30.26356947v1?rss=1">
<title>
<![CDATA[
Excess maternal deaths and maternal mortality ratios during the COVID-19 pandemic period: a global country-level counterfactual modelling study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.30.26356947v1?rss=1
</link>
<description><![CDATA[
Background: Maternal mortality remains uneven globally, and the COVID-19 pandemic disrupted maternal health services through direct infection-related risks and indirect health-system pathways. We estimated country-level deviations in maternal deaths and maternal mortality ratios (MMR) during 2020-2023 relative to pre-pandemic trends. Methods: We used WHO/UN MMEIG model-based country-level estimates of maternal deaths and MMR from 2000-2019 to fit an ensemble n-sub-epidemic forecasting model. We generated no-pandemic counterfactual projections for 2020-2023 and compared them with WHO/UN MMEIG estimates for the same years. Excess was defined as the positive difference between the WHO/UN MMEIG estimate and the counterfactual prediction; uncertainty was quantified using bootstrap-based prediction intervals. Results: Globally, estimated cumulative excess maternal deaths were 68,489 (95% UI 34,706-147,118) during 2020-2023, and the aggregate excess MMR was 10,154 (95% UI 4,568-23,744). The largest regional excess death burdens were observed in the South-East Asia Region, Eastern Mediterranean Region, and African Region. Among the eight illustrative high-burden countries, Afghanistan and Somalia had statistically detectable excess maternal deaths, with totals of 2,335 (95% UI 1,148-4,350) and 1,815 (639-3,401), respectively. Liberia had a positive median estimate of 265 excess maternal deaths, but its interval included zero (0-990). Nigeria, Chad, and South Sudan had median totals of zero, although uncertainty intervals indicated that nonzero excess could not be excluded in Chad and South Sudan. Conclusion: Pandemic-period WHO/UN MMEIG estimates deviated heterogeneously from pre-pandemic counterfactual trends. These findings should be interpreted as modeled excess relative to a no-pandemic baseline and may reflect pandemic-related disruptions together with other contemporaneous health-system, political, and social shocks, rather than directly observed deaths or causal effects attributable solely to COVID-19.
]]></description>
<dc:creator><![CDATA[ Gajjar, J. H., Karami, H., Hayes, H. A., Dixon, M. A., Massetti, G. M., Chowell, G. ]]></dc:creator>
<dc:date>2026-07-02</dc:date>
<dc:identifier>doi:10.64898/2026.06.30.26356947</dc:identifier>
<dc:title><![CDATA[Excess maternal deaths and maternal mortality ratios during the COVID-19 pandemic period: a global country-level counterfactual modelling study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.30.26356940v1?rss=1">
<title>
<![CDATA[
Multi-Omic Analyses Reveal Bidirectional Genetic Links and Convergent Inflammatory-Neuronal Signatures Between Frailty, Chronic Pain, and Rheumatoid Arthritis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.30.26356940v1?rss=1
</link>
<description><![CDATA[
Abstract Background: Frailty reflects reduced physiological resilience and increased vulnerability to stressors, functioning as a key biological marker of ageing. Yet, the molecular and causal mechanisms linking frailty to chronic inflammatory conditions remain unclear. Methods: We integrate Mendelian randomisation (MR), pairwise genome-wide association (PW-GWAS), and epigenetic-protein prediction to dissect bidirectional biological pathways between frailty, chronic pain (CP), and rheumatoid arthritis (RA). Results: Across nine genetically defined frailty phenotypes - six domain-specific factors, a general frailty factor (GF), and two cumulative indices (Frailty Index - FI, Fried Frailty Score - FFS) - MR revealed widespread causal effects of CP and RA on frailty. Genetic liability to higher chronic pain robustly increased frailty severity across the cumulative frailty measures (FI and FFS) and the disability-related frailty domain (F6), with the strongest effect observed for the Frailty Index ({beta} = 0.70, p = 7.9 x 10-52), while cumulative frailty also elevated pain risk ({beta} = 0.37, p = 2.6 x 10-13), supporting a reciprocal feedback model. RA exerted more selective effects, increasing cumulative frailty (FI and FFS) and disability-related frailty (F6), whereas the general frailty factor increased RA susceptibility (OR = 4.59, p = 9.5 x 10-8). Notably, the multimorbidity-related frailty domain showed an inverse effect on RA risk (OR = 0.65, p = 0.0078), suggesting immune adaptation or exhaustion within advanced frailty states. PW-GWAS and fine-mapping revealed shared causal loci linking inflammation, metabolism, and neurostructural pathways - SLC39A8, NLGN1, IL2RA, ERBB3, and MAGI3 - highlighting neuroimmune and synaptic processes as convergent ageing pathways. Epigenetic-proteomic analyses further identified two opposing axes: inflammatory and complement proteins (CRP, C5, CCL18, STC1) positively associated with frailty, versus neuronal adhesion and extracellular matrix (ECM) proteins (NCAM1, CNTN4, NTRK3, ADAMTS13) conferring resilience. Conclusion: Together, these findings redefine frailty as a biologically dynamic interface between inflammation and structural maintenance, where opposing molecular pathways shape vulnerability and resilience. This integrative framework highlights frailty as both a biomarker and potential intervention target, linking inflammatory dysregulation to modifiable trajectories of functional ageing.
]]></description>
<dc:creator><![CDATA[ Flint, J. P., Mitchell, B. L., Heyworth, S. M., Smith, H. M., Foote, I. F., Cox, S. R., Luciano, M. R., Lupton, M. K. ]]></dc:creator>
<dc:date>2026-07-02</dc:date>
<dc:identifier>doi:10.64898/2026.06.30.26356940</dc:identifier>
<dc:title><![CDATA[Multi-Omic Analyses Reveal Bidirectional Genetic Links and Convergent Inflammatory-Neuronal Signatures Between Frailty, Chronic Pain, and Rheumatoid Arthritis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.29.26356808v1?rss=1">
<title>
<![CDATA[
Causal effect of loss to follow-up on mortality in a population-based tuberculosis cohort in Brazil 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.29.26356808v1?rss=1
</link>
<description><![CDATA[
BackgroundLoss to follow-up (LTFU) during tuberculosis treatment is a major programmatic gap, but its causal effect on mortality has been difficult to quantify. We estimated this effect using a sequential landmark cohort analysis.

Methods and FindingsWe constructed a retrospective cohort of individuals aged [&ge;]15 years initiating their first tuberculosis treatment in Sao Paulo State, Brazil (2013-2023), using the State registry (TBweb) linked to the national mortality system (SIM). To account for immortal-time bias, we compared mortality between LTFU and continued-treatment patients in time-aligned monthly cohorts, applying a symmetric 30-day grace period to align eligibility. Cause-specific Cox models estimated adjusted hazard ratios for late (6-24 month) mortality, with non-TB mortality as a within-cohort negative control. We also computed standardized (g-formula) absolute mortality risk differences over the same window. Effect modification was assessed across pre-specified subgroups (age, sex, HIV, homelessness, drug-resistance status, calendar period). Of 171,048 individuals initiating tuberculosis therapy, 20,830 (12.2%) experienced LTFU. LTFU at any month substantially increased late mortality (adjusted hazard ratios [aHR] 1.83 [95% CI 1.27-2.64] to 2.85 [2.34-3.48] by month of LTFU), corresponding to standardized late-window mortality risk differences of up to 1.6 percentage points. The excess was concentrated in TB-attributable deaths (aHR 1.60-4.36) and was essentially null for non-TB mortality (0.96-1.48). Relative effects were largest in younger, stably housed individuals with low baseline mortality, whereas the largest absolute excess fell on people living with HIV (risk difference 3.0 percentage points).

ConclusionsLTFU at any point in tuberculosis therapy substantially increased late TB-attributable mortality, consistent with a causal pathway through interrupted treatment. Preventing LTFU should be a programmatic priority.
]]></description>
<dc:creator><![CDATA[ Lepka de Lima, E., Lindoso, A. A., Orlandi, G., Fukasava, S., Martinez, C., Croda, J., Horsburgh, C. R., Ranzani, O., Brooks, M. B., Andrews, J. R. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.29.26356808</dc:identifier>
<dc:title><![CDATA[Causal effect of loss to follow-up on mortality in a population-based tuberculosis cohort in Brazil]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.24.26356335v1?rss=1">
<title>
<![CDATA[
The national burden from Onyongnyong and chikungunya viruses in Cameroon 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.24.26356335v1?rss=1
</link>
<description><![CDATA[
Onyong-nyong (ONNV) and chikungunya (CHIKV) are arboviruses that have been identified nearly throughout Africa. However, the disease burden from the viruses has been rarely quantified as surveillance systems are poorly equipped to identify cases. Here, we tested 6,324 serum samples collected as part of the Yellow Fever testing program between 2010 and 2023 in individuals of all ages from all the health districts of Cameroon. We used a novel multiplex assay that incorporated antigens from three alphaviruses (ONNV, CHIKV and MAYV) and mathematical models that explicitly consider cross-reactivity to reconstruct individual and population infection histories for each virus. We found that despite no cases reported in Cameroon, ONNV has circulated endemically across the country for decades with an average of 332,000 annual infections and 8 million individuals with a history of infection. By contrast, we found evidence of only sporadic CHIKV outbreaks, with an estimated prevalence of 1.7%. Models that did not explicitly consider cross-reactivity between the alphaviruses lead to incorrect conclusions about the circulation of the viruses. This work highlights the need for systematic efforts to identify ONNV incident cases and the development of a vaccine development investment case against this neglected pathogen.
]]></description>
<dc:creator><![CDATA[ Ngu Njei, A., Puri, A., White, M., Garcia, L., Lambert, C., Jakpou, S., Brice Tchatchueng Mbougu, J., Cortes-Azuero, O., Weaver, S. C., Salje, H., Njouom, R. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.24.26356335</dc:identifier>
<dc:title><![CDATA[The national burden from Onyongnyong and chikungunya viruses in Cameroon]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.29.26356899v1?rss=1">
<title>
<![CDATA[
EpiCity: An AI-Enabled Epidemic-Aware Smart City Health Intelligence Framework for Sustainable Urban Planning 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.29.26356899v1?rss=1
</link>
<description><![CDATA[
Urban centres across the world remain structurally unprepared for epidemic events, lacking the real-time intelligence infrastructure needed to anticipate out-breaks, model population-level spread, and evaluate competing health interven-tions before crises escalate. This chapter presents EpiCity, an open-source, AI-enabled epidemic-aware smart city health intelligence framework designed to embed probabilistic outbreak forecasting directly into the urban planning and administrative decision cycle. EpiCity integrates four technical contributions within a unified deployable dashboard: a hybrid ensemble probabilistic fore-casting engine driven by more than 500 Monte Carlo simulations; an agent-based urban population digital twin that models SEIRD-compartment epidemic dynamics across 200 heterogeneous agents over a 60-day simulation horizon; an intervention policy scenario comparison module for quantitative evaluation of non-pharmaceutical and pharmaceutical control strategies; and a Retrieval-Augmented Generation (RAG) explainable AI chatbot that translates model outputs into plain-language guidance for city officials without specialist epidemi-ological training. Real-world validation against Johns Hopkins CSSE COVID-19 surveillance data for the United States (June-July 2020) yielded a Pearson cor-relation of 0.88 between framework forecasts and observed case trajectories, with ensemble prediction intervals achieving 90% empirical coverage, confirming the calibration reliability of the uncertainty quantification pipeline. A representa-tive simulation scenario demonstrated a 99% reduction in simulated peak case load relative to an unmitigated baseline, with an estimated 56 lives saved in the comparison period. Aligned with SDG 3 (Good Health and Well-being), SDG 11 (Sustainable Cities and Communities), and SDG 13 (Climate Action), EpiCity offers urban planners, public health officers, and city administrators a scientifically grounded yet practically accessible tool for evidence-based epi-demic preparedness and resilient city governance. The code is available at https://github.com/Harmi-kotak22/Artificial_Life_Simulator.
]]></description>
<dc:creator><![CDATA[ Kotak, H., Vala, S., Mehta, A. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.29.26356899</dc:identifier>
<dc:title><![CDATA[EpiCity: An AI-Enabled Epidemic-Aware Smart City Health Intelligence Framework for Sustainable Urban Planning]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.30.26356834v1?rss=1">
<title>
<![CDATA[
Evaluating Open-Source Wrist-Worn Accelerometer Models for Sedentary Time Detection Against Thigh-Worn Accelerometer Data 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.30.26356834v1?rss=1
</link>
<description><![CDATA[
ObjectiveWrist-worn accelerometers are common in large-scale epidemiological studies, but their ability to measure sedentary behaviour in free-living environments is unknown. We therefore aimed to evaluate the accuracy of openly-available methods to infer sedentary time from wrist-worn accelerometers.

MethodsWe analysed data from 662 working-age adults in the SMART Work & Life study (20-70 years; mean age 45 years; 72% female) who concurrently wore wrist- and thigh-worn accelerometers for up to eight free-living days. Reference measurements of sedentary time were derived from the thigh accelerometer data using proprietary algorithms. Wrist accelerometer data were processed using widely used, publicly available activity recognition models. Performance was evaluated at 30-second epochs to generate per-participant metrics, alongside comparisons of mean daily sedentary time, mean daily number of prolonged sedentary bouts ([&ge;] 30 minutes) and proportion of sedentary time in prolonged bouts. Model performance was examined across subgroups defined by age, sex, body mass index, season, recruitment centre, and in sensitivity analyses restricted to daytime hours (08:00-22:00).

ResultsThe best performing machine learning model (Actinet) accurately classified sedentary time from wrist-worn accelerometer data with a mean per-participant accuracy of 0.87 and F1 score of 0.85. Cut point-based approaches demonstrated lower accuracy of 0.80 (F1 score of 0.79). The ActiNet machine learning model showed strong agreement in daily sedentary time, daily number of prolonged sedentary bouts and proportion of sedentary time in prolonged bouts, all within 10% of the free-living thigh reference. Findings were consistent across subgroups and in analyses restricted to daytime hours.

ConclusionWrist-worn accelerometers can provide accurate measurements of sedentary behaviour in free-living settings, when assessed using current machine learning models, particularly ActiNet. This work provides confidence in future epidemiological research to examine sedentary behaviour patterns from wrist-worn accelerometers and their associations with health outcomes.
]]></description>
<dc:creator><![CDATA[ Acquah, A., Broomberg, K., Dunstan, D. W., Healy, G. N., Davies, M. J., Edwardson, C. L., Doherty, A., Maylor, B. D. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.30.26356834</dc:identifier>
<dc:title><![CDATA[Evaluating Open-Source Wrist-Worn Accelerometer Models for Sedentary Time Detection Against Thigh-Worn Accelerometer Data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.27.26356735v1?rss=1">
<title>
<![CDATA[
Impact of sequential adjustment on the association between metabolic syndrome and stroke: A population-based study in Korea 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.27.26356735v1?rss=1
</link>
<description><![CDATA[
BackgroundStroke is among the foremost contributors to mortality and lasting disability and continues to place a heavy clinical and societal burden worldwide. Although metabolic syndrome (MetS) is recognized as a contributor to stroke risk, insufficient attention has been paid to how this relationship behaves when potential confounders are entered into the model in a stepwise manner.

ObjectivesThis study aimed to characterize the relationship between MetS and stroke prevalence using a series of sequentially adjusted models built from the Korea National Health and Nutrition Examination Survey (KNHANES). We explored whether self-rated health is a useful functional indicator for stratifying stroke risk.

MethodsOf the 22,559 KNHANES VIII respondents, 12,536 participants aged [&ge;]19 years and with information required to classify physician-diagnosed stroke (DI3_dg) or define MetS were included in the final analysis. Associations were estimated using complex-sample logistic regression under a sequential adjustment scheme: Model 1 (unadjusted), Model 2 (adjusted for age and sex), Model 3 (further adjusted for educational level and family history of stroke), and Model 4 (additionally incorporating economic activity status and self-rated health).

ResultsMetS was associated with an increased risk of stroke in all models: Model 1 (odds ratio [OR] 3.372, 95% confidence interval [CI] 2.443-4.654), Model 2 (OR 1.956, 95% CI 1.396-2.740), Model 3 (OR 1.813, 95% CI 1.292-2.546), and Model 4 (OR 1.636, 95% CI 1.153-2.321). A graded pattern was noted concerning self-rated health, with progressively poorer perceived health corresponding to higher odds of stroke, and the "very poor" category showed substantially elevated odds (OR 9.836 in Model 4).

ConclusionsMetS was independently associated with stroke prevalence even after sequential adjustment. Self-rated health appears to capture both metabolic burden and broader functional health aspects.
]]></description>
<dc:creator><![CDATA[ Chae, S. H., Moon, I. Y., Yi, C. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.27.26356735</dc:identifier>
<dc:title><![CDATA[Impact of sequential adjustment on the association between metabolic syndrome and stroke: A population-based study in Korea]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.29.26354430v1?rss=1">
<title>
<![CDATA[
Impact of the HPV vaccination programme on anal HPV infection in gay, bisexual and other men who have sex with men: multi-site enhanced surveillance study in specialist sexual health services in England 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.29.26354430v1?rss=1
</link>
<description><![CDATA[
BackgroundA national human papillomavirus (HPV) vaccination programme for gay, bisexual, and other men who have sex with men (GBMSM) in England began in 2016. We evaluated the impact of this programme by monitoring the prevalence of type-specific HPV infections over time.

MethodsResidual rectal swab specimens were collected from GBMSM aged [&le;]45 years undergoing chlamydia and/or gonorrhoea screening at 10 SHS between 2017-19 (Phase 1) and 2021-24 (Phase 2). Specimens were linked to data on sociodemographic characteristics, previous STI diagnoses, and HPV vaccination reported to UKHSAs national STI surveillance system. Anonymised specimens were tested for type-specific HPV DNA using an in-house multiplex PCR and Luminex-based genotyping test. We compared the prevalence of vaccine-type HPV in each phase, and in those with and without any reported HPV vaccinations.

ResultsData from 5,787 rectal swab specimens with HPV testing results were analysed: 3,291 in Phase 1 and 2,496 in Phase 2. There was a 36% decline in the prevalence of anal HPV16/18 infection between Phase 1 and Phase 2. Overall, the prevalence of HPV16/18 was similar in GBMSM with (16.6%; 95% CI 15.2-18.1) and without reported HPV vaccination (15.8%; 95% CI 14.5-17.1).

ConclusionEight years after HPV vaccination of GBMSM began, the prevalence of vaccine-type HPV in GBMSM has declined. Vaccine effectiveness estimates were uncertain, likely due to the combined effects of underreporting of vaccinations, herd protection, and bias in vaccination uptake. These findings, albeit ecological, bode well for this targeted programme meeting its aim of reducing HPV-related diseases amongst GBMSM and reducing health inequalities.
]]></description>
<dc:creator><![CDATA[ Checchi, M., Panwar, K., French, C. E., Mohammed, H., Beddows, S., Hickman, M., Soldan, K. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.29.26354430</dc:identifier>
<dc:title><![CDATA[Impact of the HPV vaccination programme on anal HPV infection in gay, bisexual and other men who have sex with men: multi-site enhanced surveillance study in specialist sexual health services in England]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.24.26356254v1?rss=1">
<title>
<![CDATA[
The Inflammatory Cascade Through Discrimination, Socioeconomic Status, and Body-Mass Index 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.24.26356254v1?rss=1
</link>
<description><![CDATA[
C-Reactive Protein (hs-CRP) is a common marker for human inflammation, a response to perceived threat and precipitate to many compromising health conditions. Previous work demonstrated that in addition to other biological features that may be predictive and explanatory of variance in inflammation, psychosocial influences may play a role. The present work uses structural equation modeling to examine pathways including socioeconomic status (SES), psychological capital (PsyCap), and perceived discrimination (Discrim)-insofar as they explain variance in hs-CRP, potentially moderated by neurological lateralization (handedness). Body mass index (BMI), an indicator of body composition, stood as the strongest predictor of the obesity-related inflammatory marker (ORIM). On average, females are predicted to have higher hs-CRP scores than males. The psychosocial constructs were estimated to have little to no effect on inflammation (via hs-CRP) in the analysis sample (ADD Health Study) in either group (left and right-handers) although a small, statistically non-zero indirect path is found in the retained model for right-handed participants (given statistical power for estimation). With this finding, contextual effect estimates are provided with regard to the effect of perceived discrimination on hs-CRP given the range of SES and BMI.
]]></description>
<dc:creator><![CDATA[ Espero, M. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.24.26356254</dc:identifier>
<dc:title><![CDATA[The Inflammatory Cascade Through Discrimination, Socioeconomic Status, and Body-Mass Index]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.24.26356453v1?rss=1">
<title>
<![CDATA[
Childhood emotional symptom trajectories in three generationally and socio-ethnically distinct UK birth cohorts 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.24.26356453v1?rss=1
</link>
<description><![CDATA[
BackgroundDepression and anxiety symptoms emerge early in life. We examined developmental trajectories of emotional symptoms, starting from early childhood, in three UK birth-cohorts spanning successive generations and diverse socio-ethnic contexts.

MethodsUsing data from three longitudinal, population-based UK birth-cohorts: Avon Longitudinal Study of Parents and Children (ALSPAC), Millenium Cohort Study (MCS), and Born in Bradford (BiB) we identified group-based trajectories of emotional symptoms using repeated Strengths and Difficulties Questionnaire, Emotional Subscale (SDQ-E) scores from ages 3-14y. Baseline samples comprised children with [&ge;]1 SDQ-E measure between age 3-14y (NALSPAC = 11,025; NMCS = 15,446; NBiB = 6711). Participants were born three decades apart (ALSPAC: 1990-2, MCS: 2000-2, BiB: 2007-10) in distinct socioeconomic and ethnic contexts. We characterised group membership by: female sex, non-white ethnicity, maternal depression/anxiety and IMD quintile. In ALSPAC we modelled associations between trajectories and depression/anxiety diagnoses in early adulthood (24y and 30y).

ResultsIn all cohorts 49% were female. ALSPAC had few non-white participants (4%) compared to MCS (17%) and BiB (66%). Each cohort had low-, mid- and high-level symptom trajectories. High-level trajectories comprised 6-7% of the population in each cohort. However, in younger cohorts, high-level symptom trajectories started high and persisted from age 3-5y but started low and increased in the oldest cohort. Female sex and maternal depression/anxiety were associated with higher odds of high-level or increasing symptom trajectories across all cohorts. Higher socioeconomic status and belonging to the ethnic majority was protective. Mid- and high-level symptom trajectories had higher odds of depression/anxiety diagnoses in early-adulthood in the older ALSPAC cohort.

ConclusionsDevelopmental trajectories of emotional symptoms across childhood and adolescence are broadly similar across generations and diverse social contexts. However, children born more recently and in more diverse contexts may experience more persistent, severe emotional symptoms from a young age
]]></description>
<dc:creator><![CDATA[ Fairweather, S. J., Kwong, A. S. F., Deniz, E., Hammerton, G., Khandaker, G. M., Jones, H. J. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.24.26356453</dc:identifier>
<dc:title><![CDATA[Childhood emotional symptom trajectories in three generationally and socio-ethnically distinct UK birth cohorts]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.29.26356818v1?rss=1">
<title>
<![CDATA[
Cluster analysis of ME/CFS symptoms in DecodeME reveals two subgroups and a link to onset type 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.29.26356818v1?rss=1
</link>
<description><![CDATA[
BackgroundMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating, often infection-triggered illness with no cure and no effective treatment. Marked symptom heterogeneity hampers diagnosis, disease management, and trial design. Using phenotype data from the worlds largest ME/CFS cohort, this study aimed to identify groups of patients with similar symptom profiles using cluster analysis, to assess the association between cluster membership and onset type, and to explore genetic associations with cluster membership.

MethodsThis study included 19,019 DecodeME participants, ages 16 and over, with ME/CFS in the UK, from 2022-2024. We performed a k-modes cluster analysis of individuals based on similar symptoms. Cluster metrics identified the optimal number of clusters, which were characterised and compared. A sex-stratified subgroup analysis explored differences between clusters among males and females. The association between ME/CFS onset type (infectious, non-infectious, or unknown) and cluster membership was assessed with logistic regression models, adjusting for sex, age, deprivation, and ethnicity. Genetic associations with cluster membership were assessed using a genome-wide association study.

ResultsWe identified two clusters in our study population: a high symptom burden cluster (HSBC; 57% of participants) and a lower symptom burden cluster (LSBC; 43%). The HSBC was characterised by higher prevalence of symptoms across all domains, more comorbidities, and greater illness severity. Individuals with infectious and unknown onset had 1.24 times (95% CI: 1.15-1.35) and 1.30 times (95% CI: 1.18-1.43) higher adjusted odds of HSBC membership relative to non-infectious onset, respectively. A similar pattern was observed in the sex-stratified analyses, although it showed an overall higher symptom prevalence for females and a higher proportion of females in the HSBC compared to males. No genetic variant was significantly associated with cluster membership.

ConclusionsThis large-scale cluster analysis of DecodeME symptom data reinforces that ME/CFS is a heterogeneous condition with clinical subtypes. The identification of symptom-based phenotypes, along with sex-based differences in symptom burden and cluster characteristics, highlights the importance of incorporating symptom burden and sex in future research, clinical decision-making, and public health strategies. Tailoring future interventions to these subgroups could enhance patient management and improve outcomes.

Lay SummaryMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious illness affecting tens of millions of people worldwide. Severe fatigue, cognitive symptoms (problems with thinking, concentration, or memory), and post-exertional malaise (a prolonged worsening of symptoms, or new symptoms, after even minor mental or physical effort) are core ME/CFS symptoms, though individuals can experience a wide variety of other symptoms. Some of these symptoms overlap with other illnesses, making diagnosis difficult. Determining if there are subgroups of individuals with ME/CFS that share similar symptoms can help doctors and researchers better understand the different ways that ME/CFS affects people, which could lead to improved treatments, and can help direct research into its underlying causes. The present study analysed ME/CFS symptom data from a large UK-based sample using a computer program that sorts individuals into groups purely based on their shared symptoms. Two groups were consistently found: one where people had a wide range of ME/CFS symptoms, and another where people had fewer symptoms. Females tended to have more symptoms overall and so were more likely than males to be in the group with widespread symptoms. Many individuals report that an infection triggered their ME/CFS symptoms, but there are other possible triggers (e.g., physical or emotional trauma). The study found a link between ME/CFS being triggered by an infection and having more symptoms. These findings indicate that ME/CFS is not a "one-size-fits-all" disease, that we need more research to understand what causes ME/CFS, and that healthcare should be tailored to each persons needs.
]]></description>
<dc:creator><![CDATA[ St-Jean, C., Dibble, J. J., Ponting, C. P., Prigge, R. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.29.26356818</dc:identifier>
<dc:title><![CDATA[Cluster analysis of ME/CFS symptoms in DecodeME reveals two subgroups and a link to onset type]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.27.26356627v1?rss=1">
<title>
<![CDATA[
Incidence trends of nontuberculous mycobacterial pulmonary infections in Australia, Cambodia, Japan, Thailand, and the United States 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.27.26356627v1?rss=1
</link>
<description><![CDATA[
BACKGROUNDNontuberculous mycobacteria (NTM) are environmental organisms increasingly causing chronic respiratory infection. Although NTM pulmonary infection is rising globally, most studies are single-country. This study evaluated temporal trends in pulmonary NTM incidence across Queensland (Australia), Phnom Penh (Cambodia), Japan, Thailand, and the United States (US), and described regional species distribution.

METHODSLaboratory and insurance claims data were used. Incident infections were defined using region-specific criteria. For Queensland, Japan, and Thailand, data and denominators covered entire regions. US estimates included Medicare beneficiaries aged [&ge;]65 years, and Cambodian incidence was estimated from Phnom Penh data and standardised nationally. Incidence rates per 100,000 population and incidence rate ratios (IRRs) were calculated overall and by sex. Age-stratified analyses and species distributions were summarised where data were available.

RESULTSPulmonary NTM incidence increased in all regions and was highest in Japan (47.20-57.40 per 100,000) and lowest in Phnom Penh (0.23-0.38). Queensland showed the largest increase over 24 years (IRR 7.06, p<0.0001). Female predominance occurred in high-income regions, whereas Thailand showed ~1.5-fold male predominance and Phnom Penh showed no sex predominance. Incidence was higher among individuals aged [&ge;]60 years. Mycobacterium avium complex predominated in Japan and Queensland, and M. abscessus in Thailand and Phnom Penh.

CONCLUSIONSPulmonary NTM incidence increased in all regions, varying by demographic patterns and species distribution. Differences largely reflect under-ascertainment related to diagnostic capacity and tuberculosis-focused health systems rather than true infection burden. Strengthened surveillance and diagnostic capacity are needed to define the global burden of NTM pulmonary infection.

KEY MESSAGESO_LIPulmonary NTM incidence increased across all five study regions, however varied substantially by region, age, sex, and species.
C_LIO_LIThis study provides the first NTM incidence estimates from Thailand and Cambodia, where limited diagnostic capacity and tuberculosis-focused health systems influence observed incidence.
C_LIO_LICombining laboratory and claims data across high- and middle-income regions provides robust, comparable estimates to inform NTM surveillance and public health planning.
C_LI
]]></description>
<dc:creator><![CDATA[ Pradana, A. R., Ashcroft, M. M., Watthanasiri, P., Mercaldo, R. A., Kawatsu, L., Morino, E., Ung, S., Yek, C., Matsumoto-Takahashi, E., Goh, F., Khemnak, K., Wongsanuphat, S., Thammawijaya, P., Tipkrua, N., Pomchiangpin, S., Cheng, S., Morimoto, K., Mahasirimongkol, S., Prevots, D. R., Thomson, R. M. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.27.26356627</dc:identifier>
<dc:title><![CDATA[Incidence trends of nontuberculous mycobacterial pulmonary infections in Australia, Cambodia, Japan, Thailand, and the United States]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.29.26356883v1?rss=1">
<title>
<![CDATA[
Variability in US COVID Mortality, Viral Evolution, and the Emergence of Acquired Social Immune Dysfunction 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.29.26356883v1?rss=1
</link>
<description><![CDATA[
BackgroundThe course of a pandemic depends on viral traits, available public health interventions, implementation, and individual behavior, all of which interact and vary over time and space. Understanding COVID-19 therefore requires considering these factors together.

MethodsNational mortality, state-level mortality per 100,000 population for four representative states, policy stringency, and vaccination coverage were assembled from publicly available sources for February 2020 through September 2022. Viral traits, mutation rates, and vaccine effectiveness were drawn from published systematic reviews and standardized relative to wild-type values.

ResultsEach state experienced a different worst wave, separated by as much as 18 months, with up to a 24-fold difference in state mortality during major waves. NPI stringency was initially high and responsive to COVID waves, but declined during 2021 in both magnitude and responsiveness as vaccination levels rose, then flattened. Viral evolution first increased transmissibility; as population immunity rose, immune escape increased sharply, particularly with Omicron, which produced similar mortality peaks in all four states and the second largest national peak.

ConclusionsCOVID-19 did not unfold as a single national pandemic but as regionally divergent epidemics that fragmented public perception and weakened cohesion. At the same time, SARS-CoV-2 evolved traits that reduced the apparent and actual effectiveness of interventions. Omicron brought these processes together: despite producing one of the largest national mortality waves, it elicited little renewed policy activation or booster uptake. I describe this progressive uncoupling of epidemic threat, intervention effectiveness, policy activation, and public compliance as Acquired Social Immune Dysfunction.
]]></description>
<dc:creator><![CDATA[ Morris, R. D. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.29.26356883</dc:identifier>
<dc:title><![CDATA[Variability in US COVID Mortality, Viral Evolution, and the Emergence of Acquired Social Immune Dysfunction]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.28.26356782v1?rss=1">
<title>
<![CDATA[
Heterogeneity across race and ethnicity for menopause onset 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.28.26356782v1?rss=1
</link>
<description><![CDATA[
The heterogeneity onset of menopause varies across racial and ethnic groups, yet this heterogeneity may partially reflect methodological differences rather than true biological differences. Using the All of Us Research Program Controlled Tier dataset (v8), we analyzed age at first menopause diagnosis across three progressively refined cohorts: a full ICD-based cohort (Cohort 1, n = 11,306), a survey-linked subcohort adjusted for neighborhood deprivation, smoking, and alcohol use (Cohort 2, n = 10,639), and a confirmatory sensitivity cohort applying SNOMED-based surgical exclusions to the same adjusted framework (Cohort 3, n = 10,222). Asian & Pacific Islander and Indigenous/Other individuals experienced significantly earlier menopause onset than White individuals across both adjusted cohorts. The Black-White heterogeneity was attenuated after covariate adjustment and did not re-emerge after surgical exclusion. Current smoking was the sole significant behavioral predictor across adjusted models. These findings demonstrate that menopause definition and cohort selection critically shape estimates across race and ethnicity, and that EHR-based ascertainment combined with structured surgical exclusion yields broadly consistent adjusted results.
]]></description>
<dc:creator><![CDATA[ Pasumarthy, S., Hurley, M., Chen, I. Y., Thakkar, N., Agrawal, M., Hswen, Y. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.28.26356782</dc:identifier>
<dc:title><![CDATA[Heterogeneity across race and ethnicity for menopause onset]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.24.26356456v1?rss=1">
<title>
<![CDATA[
Measles Virus Genomic Surveillance Gaps during a Nationwide Outbreak, Bangladesh, 2026 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.24.26356456v1?rss=1
</link>
<description><![CDATA[
Bangladesh reported a nationwide measles outbreak in April 2026 involving over 19,000 suspected cases, despite high reported first-dose vaccine coverage ([&ge;]95%). We assessed whether publicly available molecular data could support epidemiologic interpretation of this resurgence and evaluated broader sequence sharing practices across South Asia. We analyzed public outbreak reports, WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), PubMed indexed literature, and NCBI GenBank records from nine regional countries. Public sequence visibility across the region was highly uneven. While India and Pakistan associated records dominated the public dataset, only 32 Bangladesh origin records were retrieved, and notably, none were collected after 2019. The sole 2026 Bangladesh linked molecular record was a travel associated genotype B3 genome isolated in Australia (PZ189094.1). Its closest public N450 relative was a contemporaneous Pakistan sequence (2-nucleotide difference). The historical Bangladesh sequences were more distant, precluding robust phylogenetic inference regarding local viral persistence, cross-border importation, or transmission direction. Immunization data revealed a high regional baseline but highlighted subnational vulnerability and a significant pandemic era coverage collapse in neighboring Myanmar. The absence of timely, publicly available genomic data during the critical early months of the outbreak highlights a severe genomic surveillance gap. Public molecular records were historically sparse and insufficient to reconstruct outbreak transmission dynamics. To support elimination goals, establishing targeted sequencing pipelines, enforcing minimum metadata standards, and ensuring rapid public data deposition are urgently needed.
]]></description>
<dc:creator><![CDATA[ Hasnain, N., Shihab, S. F., Islam, M. A., Rahman, M. A. ]]></dc:creator>
<dc:date>2026-07-01</dc:date>
<dc:identifier>doi:10.64898/2026.06.24.26356456</dc:identifier>
<dc:title><![CDATA[Measles Virus Genomic Surveillance Gaps during a Nationwide Outbreak, Bangladesh, 2026]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-07-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.26.26356705v1?rss=1">
<title>
<![CDATA[
Health conditions and RSV-related Pediatric Intensive Care Unit admissions in children during their second RSV season 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.26.26356705v1?rss=1
</link>
<description><![CDATA[
ImportanceRespiratory syncytial virus (RSV) hospitalization rates are highest among children <2 years of age. RSV immunization with infant monoclonal antibody or maternal vaccine is recommended to protect all U.S. infants in their first RSV season. For certain high-risk children aged 8-19 months entering their second RSV season, the monoclonal antibody nirsevimab is recommended. Little is known regarding preexisting health conditions as risk factors for RSV-associated respiratory failure in children during their second season.

ObjectivesTo describe children admitted to the pediatric intensive care unit (PICU) for RSV during their second RSV season by preexisting health conditions, and to compare demographic and clinical characteristics across groups.

Design, Setting, and ParticipantsSurveillance registry of children 8-<24 months old admitted to the PICU in 30 pediatric hospitals in the 2023-2024/2024-2025 RSV seasons. All children had an RSV-positive respiratory sample and received respiratory support with high flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation (IMV).

ExposurePreexisting health conditions potentially increasing risk of severe RSV disease.

Main Outcomes and MeasuresPatients were classified into four mutually exclusive groups by preexisting health conditions: 1) U.S. nirsevimab eligible criteria, 2) other identified RSV risk conditions (with some evidence of increased risk for severe RSV), 3) other preexisting conditions, and 4) no preexisting conditions. Patient demographic characteristics and level of respiratory support received were compared.

ResultsAmong 574 children: 47 (8.2%) had U.S. nirsevimab eligibility criteria, 76 (13.2%) had other RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had none. A higher proportion of children with nirsevimab eligibility factors (40.4%) than those with other identified RSV risk conditions (17.1%) required IMV, which was higher than other (10.4%) or no (5.9%) preexisting health conditions (ptrend<0.001).

Conclusions and RelevanceApproximately 20% of children admitted to the PICU with severe RSV were in the defined groups that met U.S. nirsevimab-eligibility criteria or that had an identified RSV risk condition associated with known risk for severe RSV. A considerable proportion of both groups of children required IMV for respiratory support. These findings may help inform future deliberations regarding U.S. second season nirsevimab-eligibility recommendations.

Key PointsO_ST_ABSQuestionC_ST_ABSWhat preexisting health conditions are present in children aged 8-<24 months admitted to the pediatric intensive care unit for severe RSV disease in their second RSV season and how do clinical outcomes differ?

FindingsAmong 574 children, 8% were eligible for nirsevimab in the U.S. and 13% had other preexisting conditions with known risk for severe RSV. Children with preexisting conditions, particularly those eligible for nirsevimab, were more likely to require invasive mechanical ventilation than those without.

MeaningThese findings may inform future deliberations regarding which children in their second RSV season might benefit from RSV preventive products.
]]></description>
<dc:creator><![CDATA[ Simeone, R. M., Zambrano, L., Newhams, M. M., Payne, A. B., Orzel-Lockwood, A. O., Halasa, N. B., Calixte, J., Maddux, A. B., Chiotos, K., Kamidani, S., Crandall, H., Zerr, D. M., Cameron, M. A., Gertz, S. J., Coates, B. M., Michelson, K. N., Schuster, J. E., Nofziger, R. A., Chauhan, J. C., Maamari, M., Shein, S. L., Kong, M., Hume, J. R., Martine, L. M., Guzman-Cottrill, J. A., Bhumbra, S. S., Irby, K., Allen Staat, M., Bradford, T. T., Wellnitz, K., Stockwell, M. S., Zinter, M., Schwartz, S. P., Hymes, S., Levy, E. R., Biggs, A., Lindsey, K., Campbell, A. P., Randolph, A. G. ]]></dc:creator>
<dc:date>2026-06-30</dc:date>
<dc:identifier>doi:10.64898/2026.06.26.26356705</dc:identifier>
<dc:title><![CDATA[Health conditions and RSV-related Pediatric Intensive Care Unit admissions in children during their second RSV season]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.26.26356648v1?rss=1">
<title>
<![CDATA[
Adaptive multi-model ensembles for improved epidemic projections and decision support 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.26.26356648v1?rss=1
</link>
<description><![CDATA[
In recent years, the use of multi-model ensemble projections in infectious disease modeling has become an established methodological approach to account for and integrate across uncertainties and structural differences present in individual models. However, the creation of long-term ensemble projections through these coordinated efforts is resource-intensive, demanding the input of multiple research teams and substantial computational power. This typically limits the ability to refine projections, update the selection of plausible epidemic trajectories, or expand the number of scenarios that can be assessed, even as new empirical data become available. To address this challenge, we define an adaptive ensemble approach that, analogously to a multi-model particle filtering method, dynamically selects individual model trajectories based on observed data throughout the epidemic projection period. We demonstrate the effectiveness of this methodology using the U.S. Flu Scenario Modeling Hub (SMH) projections for influenza hospitalizations in the United States during the 2023-2024 and 2024-2025 winter seasons. Our findings show that the adaptive ensemble yields improved predictive accuracy with respect to the original SMH ensemble projections across several scoring rules and geographical resolutions. Furthermore, the adaptive ensemble approach offers two additional applications: i) the dynamic assignment of posterior probabilities to epidemic scenarios, identifying the most plausible scenario, and representing how reality is captured by a combination of scenarios, and ii) the potential use for short-term forecasting. The adaptive ensemble approach is able to identify the most likely scenarios for the 2023-2024 and 2024-2025 U.S. influenza seasons, even in the early stages of the epidemic. It outperforms, retrospectively, a baseline model in short-term forecasting of influenza hospitalizations in the United States during the two seasons across various horizons and scoring rules, showing potential to contribute to real-time collaborative forecasting challenges such as CDCs FluSight. The proposed approach offers an efficient or low-resource strategy to increase the impact of multi-model epidemic projections by providing real-time support to modeling teams, public health authorities, and decision-makers.
]]></description>
<dc:creator><![CDATA[ Fiandrino, S., Paolotti, D., Bay, C., Chinazzi, M., Davis, J. T., Bents, S. J., Perofsky, A. C., Turtle, J. A., Riley, P., Ben-Nun, M., Moore, S. M., Perkins, A., Camargo Espana, G. F., Srivastava, A., Aawar, M. A., Bandekar, S. R., Bi, K., Bouchnita, A., Fox, S. J., Meyers, L. A., Venkatramanan, S., Porebski, P., Adiga, A., Lewis, B., Marathe, M., Haghpanah, F., Klein, E., Loo, S. L., Jung, S.-m., Smith, C. P., Contamin, L., Hochheiser, H., Carcelen, E. C., Howerton, E., Shea, K., Yan, K., Runge, M. C., Viboud, C., Pearson, C. A. B., Truelove, S. A., Lessler, J., Borchering, R., Biggerstaff ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.26.26356648</dc:identifier>
<dc:title><![CDATA[Adaptive multi-model ensembles for improved epidemic projections and decision support]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.26.26356655v1?rss=1">
<title>
<![CDATA[
Spatial structure and demographic decoupling of chikungunya transmission and severity in Brazil, 2015 to 2025 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.26.26356655v1?rss=1
</link>
<description><![CDATA[
Brazil bears one of the largest chikungunya burdens in the Americas (more than 1{middle dot}2 million confirmed cases since 2014), and the 2024-25 wave expanded further south than any prior outbreak. IXCHIQ entered Sistema Unico de Saude (SUS) deployment in February 2026 despite an August 2025 US FDA biologics license suspension over serious adverse events in adults aged 60 years and older; regulatory authorities in the EU (EMA), Brazil (ANVISA), and Canada maintained licensing with revised prescribing guidance requiring individual benefit-risk assessment. Evidence to guide rollout targeting is lacking.

We analyzed 1,235,424 confirmed chikungunya cases reported to Sistema de Informacao de Agravos de Notificacao SINAN (2015-2025) across 5,570 municipalities. A Bayesian hierarchical spatiotemporal model quantified spatial structure and persistence of transmission across municipalities, controlling for national arboviral co-circulation trends. Disease progression was assessed with Cox models stratified by age and sex. Municipal 2024-25 incidence rate ratios and proportions aged 65 years or older (tertiles) defined transmission-control, clinical-preparedness, and combined-priority municipalities.

Transmission epicenters shifted from the Northeast (2016-17) to the Central-West (2024-25; peak municipality IRRs >2{middle dot}7x the national median); clustering and seasonality persisted. Cases concentrated among adults aged 25 to 55, while post-hospitalization mortality rose steeply with age (HR 10{middle dot}57, 95% CI 7{middle dot}64-14{middle dot}62 for ages 80 years and older versus adults aged 20 to 29). Males had faster progression to hospitalization (HR 1{middle dot}26) and death (HR 1{middle dot}76, onset to death) despite fewer notifications. The Central-West led transmission yet had lower case fatality among hospitalized cases (3{middle dot}54%, 81 deaths out of 2,285 hospitalized) than the Southeast (4{middle dot}95%, 163 deaths out of 3,291 hospitalized), reflecting demographic rather than purely clinical differences between regions. A municipality-level allocation framework classified 832 municipalities as transmission-control priority (high recent transmission, younger population; predominantly Central-West), 832 as clinical-preparedness priority (lower transmission, older population; predominantly Southeast and South), and 461 as combined-priority (high on both dimensions; predominantly Northeast and Southeast).
]]></description>
<dc:creator><![CDATA[ Zhang, Q., Souza Campos, F., Vieira Santos de Abreu, F., de Souza, W. M., Chen, S., Bento, A. I. ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.26.26356655</dc:identifier>
<dc:title><![CDATA[Spatial structure and demographic decoupling of chikungunya transmission and severity in Brazil, 2015 to 2025]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.26.26356687v1?rss=1">
<title>
<![CDATA[
The Long-Term Outcomes of Neural Tube Defects in Eastern Africa: A Systematic Review and Meta-Analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.26.26356687v1?rss=1
</link>
<description><![CDATA[
BackgroundNeural tube defects (NTDs) are preventable congenital malformations that disproportionately affect low and middle-income countries and contribute to disability and mortality. Evidence on the long-term outcomes of children and adolescents with NTDs in Eastern Africa has not been comprehensively synthesised. We conducted a systematic review and meta-analysis to assess survival, complications, and functional outcomes among children with NTDs in this region.

MethodsWe searched PubMed, MEDLINE (Ovid), Cochrane Library, Web of Science, and Africa Index Medicus from the earliest records to April 2025. Two reviewers independently screened studies, assessed quality, and extracted data. We included studies reporting outcomes beyond one year of age, except mortality, which was assessed from birth onwards. Random-effects meta-analyses were undertaken when at least two sufficiently studies were available; otherwise, findings were synthesised narratively.

ResultsOf 597 articles screened, 16 studies involving 2,340 children with NTDs met the inclusion criteria. Pooled cumulative mortality was 23% (95% CI: 12-36%) in the neonatal period, 9% (95% CI: 2-33%) during infancy, 22% (95% CI: 16-28%) in toddlers, 37% (95% CI: 30-44%) in pre-school-aged children and 45% (95% CI: 36-54%) in school-aged children. The pooled prevalence of hydrocephalus was 41% (95% CI: 34-48%) with little variation by age. Neurogenic bladder increased from 53% (95% CI 49-81%) in toddlers to 83% (95 % CI 72-91%) in adolescents, while impaired mobility affected about 61% (95% CI 48-72%) of adolescents. School enrolment was 53% (95% CI: 39-67%), with 9% (95% CI: 4%-19%) in specialized education. Speech, hearing, and bowel dysfunction were understudied ([&le;] 2 studies each).

ConclusionMany children with NTDs in the Eastern African region survive beyond infancy but frequently experience hydrocephalus, neurogenic bladder and motor impairment. Longitudinal studies, context-specific guidelines, and follow-up systems are urgently needed to improve care and long-term outcomes.

PROSPERO registered numberCRD420251019868

What is already known on this topicO_LINTDs carry a substantial burden of mortality and lifelong disability. Survival and long-term outcomes in high-income settings are well-documented, but evidence from the Eastern African region is limited and fragmented.
C_LIO_LIExisting studies provide an incomplete picture of survival, complications, functional outcomes, and school participation beyond infancy
C_LI

What this study addsO_LIThis review demonstrates that mortality among children with NTDs increases substantially throughout childhood.
C_LIO_LIHydrocephalus, neurogenic bladder, impaired mobility, and low school enrolment are common, while bowel, speech, and hearing outcomes remain poorly reported.
C_LI

How this study might affect research practise or policyO_LIThese findings underscore the need for structured long-term follow-up and multidisciplinary care for children with NTDs encompassing rehabilitation, continence care, and inclusive education.
C_LIO_LIFuture research should prioritise prospective cohort designs with standardised outcome measurement to generate context-specific evidence
C_LI
]]></description>
<dc:creator><![CDATA[ Mwangudzah, H. M., Chemutai, J., Njiro, B. J., Cornish, R., Lewis, S. J., Power, G. M. ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.26.26356687</dc:identifier>
<dc:title><![CDATA[The Long-Term Outcomes of Neural Tube Defects in Eastern Africa: A Systematic Review and Meta-Analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.23.26355971v1?rss=1">
<title>
<![CDATA[
Sedentary behaviour and cancer risk: a World Cancer Research Fund International Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.23.26355971v1?rss=1
</link>
<description><![CDATA[
BackgroundHigh levels of sedentary behaviour are an emerging global public health concern, but its impact on cancer risk remains unclear.

MethodsWithin the Global Cancer Update Programme (CUP Global), we systematically searched the literature in PubMed and Embase until September 2024 for observational cohort studies on sedentary behaviour and adult cancer risk. Using dose-response meta-analyses, we investigated sedentary behaviour domains (total, occupational, recreational, transportation, and/or other) and dimensions (duration, frequency), and additionally pooled across domains. The quality of evidence was graded by the CUP Global Expert Panel (protocol registration: https://osf.io/7utbm/).

FindingsWe identified 62 publications from 27 cohorts comprising 162,902 incident cancer cases across 19 anatomical sites. There was evidence for a probable causal positive association between sedentary time (mixed definitions) and breast (RRper 2 hours/day=1.03; 95%CI=1.02-1.05; I2=10%; n=11 studies) and colon (RR=1.05; 95%CI=1.03-1.07; I2=0%; n=9) cancer risk, and between television watching time and colon cancer risk (RRper 2 hours/day=1.08; 95%CI=1.05-1.11; I2=0%; n=6). Limited suggestive evidence supported positive associations between sedentary time (mixed definitions) and lung (RR=1.04; 95%CI=1.00-1.09; I2=69%; n=7), ovarian (RR=1.06; 95%CI=1.01-1.10; I2=0%; n=7), premenopausal (RR=1.03; 95%CI=0.99-1.08; I2=20%; n=7) and postmenopausal breast (RR=1.02; 95%CI=1.00-1.04; I2=7%; n=11), and colorectal (RR=1.02; 95%CI=1.00-1.04; I2=47%; n=11) cancers, and between occupational sitting time and breast (RRper 2 hours/day=1.05; 95%CI=1.01-1.09; I2=0%; n=4) and colon (RR=1.08; 95%CI=1.02-1.15; I2=28%; n=2) cancers. An interactive evidence platform is available at: https://teacup.cc.ic.ac.uk/sedentary-behaviour-cancer.html.

InterpretationEvidence supports that prolonged sedentary behaviour is probably a cause of breast and colon cancers, while limited suggestive evidence supports positive associations for several other exposure-cancer pairs, including lung and ovarian cancers. This evidence should lead to revised cancer prevention recommendations. Future research should focus on device-based exposure assessments, repeated measurements, exposure substitution models, inclusion of diverse populations and investigation of biological mechanisms.

FundingWorld Cancer Research Fund network of charities (American Institute for Cancer Research; World Cancer Research Fund; Wereld Kanker Onderzoek Fonds).
]]></description>
<dc:creator><![CDATA[ Markozannes, G., Jayedi, A., Cariolou, M., Pagkalidou, E., Kazmi, S.-Z., Balducci, K., Kiss, S., Vieira, R., Cividini, S., Aune, D., Greenwood, D. C., Cross, A. J., Gunter, M. J., Zürn, S. J., Abnet, C. C., Gordon-Dseagu, V. L. Z., Maskell, K., Clary, C., Croker, H., Mitrou, P., Riboli, E., Baskin, M., Chowdhury, R., Gaudet, M., Giovannucci, E. L., Kampman, E., Lewis, S. J., May, A. M., Park, Y., Pischon, T. J., Severi, G., Hill, L., Weijenberg, M. P., Krebs, J., Tsilidis, K. K., Chan, D. S. M. ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.23.26355971</dc:identifier>
<dc:title><![CDATA[Sedentary behaviour and cancer risk: a World Cancer Research Fund International Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.25.26356562v1?rss=1">
<title>
<![CDATA[
Emergence and co-circulation of Monkeypox virus Clade Ia and Clade Ib in South Kivu, Democratic Republic of the Congo, January to May 2026 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.25.26356562v1?rss=1
</link>
<description><![CDATA[
In September 2023, the first infections with a novel lineage of mpox were detected in South Kivu. Since then, the virus has spread regionally, nationally and internationally. As part of continued efforts to understand the mpox ecology and epidemiology, the South Kivu district of public health and partners have set up systematic case finding and follow-up, including strain characterisation through PCR and sequencing. Samples were collected from 595 hospitalized patients with a confirmed mpox virus infection. A clade differentiating RT-PCR showed that 545 (92%) of samples were positive for clade Ib but also - remarkably- that Clade Ia infections were diagnosed for the first time in South Kivu. First detected in cases in week 7 in Kamituga, 50 cases were identified over the whole study period (8,40% of all cases). Phylogenetic analysis of initial cases revealed introductions of clade Ia into the South Kivu province alongside the continuation of the clade Ib mpox virus outbreak. These findings underscore the increasing complexity of clade I mpox virus outbreaks in the DRC.
]]></description>
<dc:creator><![CDATA[ Murhula, L., Udahemuka, J., Nieuwenhuijse, D. F., Chasinga, B., Sindayiheba, R., Schuele, L., Cassidy, H., Bacon Benimana, F., Chigabo, A., Bihando, J., Nzigire Barhatwira, G., Bengehya Mbiribindi, J., Ndoli Minega, J., Lang, T. A., Lulihoshi Willy, K., Ngabo, P., Mitchell, S., Gortazar, C., M. Aarestrup, F., Bahizire, E., Koopmans, M., Oude Munnink, B., Ndishimye, P. ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.25.26356562</dc:identifier>
<dc:title><![CDATA[Emergence and co-circulation of Monkeypox virus Clade Ia and Clade Ib in South Kivu, Democratic Republic of the Congo, January to May 2026]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.06.24.26356484v1?rss=1">
<title>
<![CDATA[
Trends, Rural-Urban Inequalities and Forecasts of Open Defecation in Ghana Using Joinpoint Regression and ARIMA Analysis, 2000-2030 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.06.24.26356484v1?rss=1
</link>
<description><![CDATA[
BackgroundOpen defecation remains a major public health challenge in Ghana and across sub-Saharan Africa, with persistent rural-urban inequalities undermining progress toward Sustainable Development Goal 6.2 (SDG 6.2). Despite two decades of national sanitation programming, structural and equity barriers continue to constrain progress. A repeated cross-sectional analyses combining WHO-standardised inequality measures, temporal trend modelling, and projections remain absent from the literature for Ghana.

MethodsNational, rural, and urban open defecation prevalence (2000-2024) was analysed using WHO Health Equity Assessment Toolkit (HEAT) data. Four inequality measures: Difference, Ratio, Population Attributable Risk (PAR), and Population Attributable Fraction (PAF), quantified rural-urban disparities. Joinpoint regression identified statistically significant trend inflection points across MDG and SDG eras. ARIMA models projected prevalence to 2030 under status quo, accelerated, and decelerated scenarios; hold-out validation confirmed high forecast accuracy across all series (MAPE <1%).

ResultsNational prevalence declined from 20.31% to 17.79% (AAPC: -0.55%, p<0.001), with a joinpoint at 2016 (95% CI: 2015-2017) after which decline slowed during the SDG era. Rural prevalence rose marginally (AAPC: +0.07%) with no significant joinpoints across the 25-year period; urban prevalence also increased (AAPC: +0.76%). Rural prevalence exceeded urban more than threefold by 2024 (R=3.38); PAF improved from -62.62% to -48.85%, indicating a substantial national burden attributable to rural disadvantage. Under the status quo scenario, national and rural prevalence are projected at 17.24% and 30.88% by 2030, far exceeding the SDG 6.2 threshold.

ConclusionDespite modest national progress, substantial rural-urban inequalities remain entrenched, and Ghana is unlikely to achieve SDG 6.2 under current trajectories. Accelerated, equity-focused interventions targeting structurally disadvantaged rural populations are urgently required to reduce sanitation inequalities and improve health outcomes.
]]></description>
<dc:creator><![CDATA[ Inusah, A.-W., Nwuzoh, M. I., Seidu, A.-A. ]]></dc:creator>
<dc:date>2026-06-29</dc:date>
<dc:identifier>doi:10.64898/2026.06.24.26356484</dc:identifier>
<dc:title><![CDATA[Trends, Rural-Urban Inequalities and Forecasts of Open Defecation in Ghana Using Joinpoint Regression and ARIMA Analysis, 2000-2030]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-06-29</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
